claim: johnson & johnson initiates the global phase 3 clinical trial of its janssen covid-19 vaccine candidate
evidence_1: janssens investigational covid-19 vaccine candidate the janssen covid-19 vaccine candidate leverages the companys advac® technology platform, which was also used to develop and manufacture janssens european commission-approved ebola vaccine and construct its zika, rsv, and hiv investigational vaccine candidates.", "the phase 3 ensemble and ensemble 2 trials follow positive interim results from the companys ongoing phase 1/2a clinical study, which is studying the safety profile and immunogenicity of both a single-dose and two-dose vaccination.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "in order to evaluate the efficacy of janssens covid-19 vaccine candidate, clinical trial sites in countries and areas with high incidence of covid-19 and the ability to achieve a rapid initiation were selected.", "ensemble 2 is a complementary, planned, pivotal, large-scale, multi-country phase 3 trial that will study the safety and efficacy of a two-dose regimen of the investigational janssen vaccine candidate for the prevention of covid-19 in up to 30,000 participants worldwide.", "phase 3 ensemble 2 study the phase 3 ensemble 2 study (nct04614948) is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of a two-dose vaccine regimen versus placebo in adults 18 years old and older with and without comorbidities associated with an increased risk for severe covid-19."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )